Core Viewpoint - Hillman Solutions Corp. is set to announce its earnings for the thirteen weeks ended March 28, 2026, during a conference call on April 28, 2026, at 8:30 a.m. Eastern Time [1]. Company Overview - Hillman Solutions Corp., founded in 1964 and headquartered in Cincinnati, is a prominent provider of hardware-related products and merchandising solutions, serving retail, pro distribution, and industrial MRO customers [5]. - The company has established a legacy of service and growth through strategic partnerships with leading home improvement, hardware, and farm and fleet retailers in North America [5]. - Hillman differentiates itself with a dedicated field sales team of over 1,200 associates, direct-to-store distribution capabilities, and expertise in global sourcing and supply chain [5]. - The extensive product portfolio includes more than 111,000 SKUs, covering fasteners, hardware, project gear and supplies, and key and engraving services [5]. - Hillman is recognized for exceptional customer service and innovative products, frequently earning vendor of the year accolades from top customers [5]. Earnings Call Details - The earnings release will be issued after market close on April 27, 2026, and the results presentation will be available via a listen-only webcast [1][4]. - President and CEO Jon Michael Adinolfi and CFO Rocky Kraft will lead the results presentation [2]. - Sell-side analysts must register to participate in the live Q&A session during the call [3].

Core Insights - Cloudastructure, Inc. has reaffirmed its guidance of approximately 270% year-over-year revenue growth and expects to recognize more than $5.0 million in revenue for the fiscal year 2025 [1] Company Overview - Cloudastructure is headquartered in Palo Alto, California, and is recognized for its advanced AI Surveillance and Remote Guarding solutions [2] - The company's security platform features a scalable cloud-based architecture that includes cloud video surveillance with proprietary AI/ML analytics and a seamless remote guarding solution [2] - Cloudastructure offers a value proposition that avoids proprietary hardware, providing contract-free, month-to-month pricing and unlimited 24/7 support [2] - The platform enables enterprise businesses to achieve proactive, end-to-end security and can result in up to a 75% lower Total Cost of Ownership compared to other systems [2]

Core Insights - BOS Better Online Solutions Ltd. reported record revenue and profitability for the full year 2025, indicating strong business momentum, particularly in defense-related sectors [2][4][5]. Financial Performance - **Fourth Quarter 2025 Highlights**: - Revenues reached $12.6 million, a 21.5% increase from $10.4 million in Q4 2024 [3]. - EBITDA was $944,000, up 32% from $715,000 in Q4 2024 [3]. - Net income rose to $819,000, a 68.9% increase compared to $485,000 in Q4 2024 [3]. - Earnings per share (EPS) increased to $0.12, a 50% rise from $0.08 in Q4 2024 [3]. - Cash and equivalents stood at $11.8 million, with a contracted backlog of $24 million as of December 31, 2025 [3]. - **Full Year 2025 Highlights**: - Total revenues were $50.6 million, reflecting a 26.6% growth from $39.9 million in 2024 [4]. - EBITDA increased to $4.6 million, a 42.6% rise from $3.2 million in 2024 [4]. - Net income for the year was $3.6 million, up 57% from $2.3 million in 2024 [4]. - EPS for the year was $0.59, a 47.5% increase from $0.40 in 2024 [4]. Business Segments - The supply chain division saw a revenue growth of 40% during the year, benefiting from a global diversification strategy and expanding into new markets like India [5]. - The RFID division reported an operating loss of $665,000 for the year, primarily due to a $1.2 million goodwill impairment charge. Without this charge, the division would have generated approximately $535,000 in operating income [6]. - The Intelligent Robotics division showed steady profitability improvements and increased backlog, indicating operational excellence across business units [6]. Future Outlook - The company projects 2026 revenues to be consistent with 2025 levels, estimating revenues of $51 million and net income of $3.6 million [8].

Core Viewpoint - Rio Silver Inc. has successfully closed a non-brokered private placement, raising gross proceeds of $3,000,000 by issuing 8,571,429 units at a price of $0.35 per unit [1] Group 1: Offering Details - Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant exercisable at $0.50 for 24 months, subject to early expiry conditions [2] - The securities issued are subject to a statutory hold period of four months, expiring on July 28, 2026 [2] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for the advancement of the Maria Norte Project in Peru, access development, metallurgical programs, and general working capital [3] Group 3: Investor Information - Eric Sprott, through 2176423 Ontario Ltd., acquired 5,714,285 units for a total of $1,999,999.75, and prior to the offering, he did not own any securities of the company [4] - Following the offering, Mr. Sprott beneficially owns approximately 10.0% of the common shares on an undiluted basis and 14.3% on a partially-diluted basis, assuming full exercise of the warrants [5] Group 4: Investment Intent - The securities are held for investment purposes, and Mr. Sprott has a long-term view, with potential plans to acquire additional securities or sell them depending on market conditions [6]

Core Insights - SAGA Metals Corp. has reported additional assay results from drill holes R-0021, R-0022, and R-0023, indicating consistent and high-quality mineralization at the Trapper Zone of the Radar Titanium-Vanadium-Iron Project in Labrador, Canada [1][3][8] Drilling Results - Drill hole R-0021 reported an intercept of 31.38 m at 53.18% Fe₂O₃, 7.08% TiO₂, and 0.414% V₂O₅ - Drill hole R-0022 showed 30.60 m at 49.40% Fe₂O₃, 6.61% TiO₂, and 0.373% V₂O₅ - Drill hole R-0023 had an intercept of 86 m at 45.50% Fe₂O₃, 5.50% TiO₂, and 0.367% V₂O₅ [4][8] Overall Progress - A total of 8 diamond drill holes have been reported in 2026, with significant oxide intercepts exceeding 70–90 meters and head grades frequently above 45–53% Fe₂O₃, 6–7% TiO₂, and 0.37-0.41% V₂O₅ [4][8] - The total meters drilled in the Trapper Zone for 2026 reached 8,144 m, with ongoing drilling at hole R-0046 [7][15] Geological Context - The Radar Property spans 24,175 hectares and hosts the Dykes River intrusive complex, with geological mapping confirming oxide layering across more than 20 km of strike length [19][30] - The mineralization at Radar is comparable to global Fe–Ti–V systems, positioning the project as a potential strategic supplier of titanium, vanadium, and iron to North American markets [20][22] Future Plans - The company aims to advance beneficiation studies on the oxide mineralization and deliver a maiden Mineral Resource Estimate in 2026, which will support future economic assessments [5][8]

Core Insights - Palvella Therapeutics is advancing its QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, with a New Drug Application (NDA) submission planned for the second half of 2026, potentially becoming the first FDA-approved therapy for this condition affecting over 30,000 patients in the U.S. [1][4] Research and Development Highlights - Positive topline results from the Phase 3 SELVA study for QTORIN™ rapamycin were reported, meeting the primary endpoint with a mean change of +2.13 (p<0.001) on the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA) [5] - 95% of trial participants aged 6 years and older showed improvement on the mLM-IGA at Week 24, with 86% rated as "Much Improved" or "Very Much Improved" [5] - QTORIN™ rapamycin was well-tolerated, with no serious adverse events reported and systemic levels below 2ng/mL [5] - Initiation of Phase 3 trial for cutaneous venous malformations and Phase 2 trials for clinically significant angiokeratomas and disseminated superficial actinic porokeratosis are planned for the second half of 2026 [2][12] Financial Overview - As of December 31, 2025, the company reported pro forma cash of approximately $274 million, reflecting net proceeds from a February 2026 equity financing [2][17] - Research and development expenses for 2025 were $22.8 million, up from $8.2 million in 2024, primarily due to increased clinical development activities [17] - General and administrative expenses rose to $15.8 million in 2025 from $5.9 million in 2024, attributed to increased headcount and professional services [17] - The net loss attributable to common stockholders for 2025 was $41.7 million, or $3.71 per share, compared to a loss of $17.4 million, or $7.83 per share, in 2024 [17][20] Corporate Developments - The company successfully closed an oversubscribed public offering generating $230 million in gross proceeds, enhancing its financial position [4][12] - Palvella is focused on building a leading biopharmaceutical company addressing serious, rare skin diseases and vascular malformations with no FDA-approved therapies [4][14] - Recent leadership appointments aim to strengthen the company's market access and human resources capabilities [12]

Core Insights - AGA Precision Systems LLC has entered into a Long-Term Agreement (LTA) with Turbo-Jet Products Co., Inc. to supply mission-critical aerospace and defense components [1][2] Group 1: Agreement Details - The LTA has an initial term of five years with provisions for annual renewals, establishing a long-term strategic supply relationship [2] - The agreement framework governs all future purchase orders during the LTA's term, enhancing operational efficiency [2] Group 2: Strategic Importance - The LTA strengthens AGA's position within the aerospace and defense supply chain, enabling support for U.S. government and defense-related contracts [3] - Compliance with Federal Acquisition Regulation (FAR) and Defense Federal Acquisition Regulation Supplement (DFARS) requirements is emphasized [3] Group 3: Quality Certifications - AGA has achieved AS9100 certification, a globally recognized quality standard for aerospace manufacturing, and is compliant with International Traffic in Arms Regulations (ITAR) [4][6] - These certifications reinforce AGA's capability to deliver high-quality, traceable components for regulated defense programs [4] Group 4: Company Background - AGA Precision Systems LLC specializes in high-tolerance milling, turning, mold manufacturing, and machining of complex metals, serving various sectors including aerospace and defense [5] - Turbo-Jet Products Co., Inc. has been providing custom design and manufacturing solutions for aerospace and military industries since 1948, and is also AS9100 Rev. D / ISO 9001:2015 certified [7]

Core Insights - MiNK Therapeutics, Inc. reported financial results for Q4 and full year 2025, highlighting a focus on immune restoration therapies for autoimmune and inflammatory diseases, as well as cancer treatment [1][2] Financial Performance - The company ended 2025 with a cash balance of $13.4 million, having raised an additional $3.0 million since year-end through an at-the-market sales agreement [10] - The net loss for Q4 2025 was $2.6 million, or $0.56 per share, compared to a net loss of $2.5 million, or $0.62 per share for Q4 2024 [10][15] - For the full year 2025, the net loss was $12.5 million, or $2.93 per share, compared to $10.8 million, or $2.86 per share for 2024 [10][15] Clinical Development and Pipeline - MiNK's lead candidate, agenT-797, is advancing in a randomized Phase 2 trial for hypoxemic pneumonia/ARDS, a condition affecting approximately 200,000–300,000 patients annually in the U.S. and Europe [3][6] - The company is also focusing on the development of agenT-797 for graft-versus-host disease (GVHD), supported by a NIH STTR grant and a philanthropic award, with clinical trial launch expected in 1H 2026 [5][9] - Data presented at SITC 2025 indicated that agenT-797 can deliver durable clinical benefits in heavily pretreated, checkpoint-refractory solid tumors [4][7] Strategic Partnerships and Funding - The company has established strategic partnerships and secured non-dilutive funding, including a collaboration with the C-Further Consortium, which provides up to $1.1 million in funding for pediatric oncology programs [6][14] - The recognition of MiNK's platform potential is reflected in the awards and grants received, which are expected to accelerate clinical development [2][9] Leadership and Operational Readiness - MiNK has strengthened its financial leadership with the appointment of Melissa Orillal as Principal Financial Officer, focusing on capital allocation and operational execution [8][14] - The company is transitioning from early-stage development to a more execution-driven clinical-stage biopharmaceutical company [8]

Core Viewpoint - Plus Therapeutics, Inc. has announced a reverse stock split at a ratio of 1-for-25 to comply with Nasdaq's minimum bid price requirement of $1.00 for continued listing [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. Eastern Time on April 2, 2026, reducing the outstanding common stock from approximately 171,550,698 shares to about 6,862,027 shares [1][3]. - Every 25 shares of Plus Therapeutics common stock will be combined into one share, with no change to the par value of $0.001 per share [3]. - Holders of fractional shares will receive a cash payment instead of fractional shares, and the shares underlying the Company's outstanding equity awards and warrants will also be adjusted accordingly [3]. Group 2: Stockholder Instructions - The Company has retained Broadridge Financial Services, Inc. as the exchange agent for the reverse stock split, providing instructions for stockholders with shares in certificate form [4]. - Stockholders holding shares in book-entry form or brokerage accounts will see the impact of the reverse stock split reflected in their accounts without needing to take action [4]. Group 3: Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, aiming to enhance clinical outcomes [5]. - The Company is advancing a pipeline of product candidates, particularly in leptomeningeal metastases and recurrent glioblastoma, supported by strategic partnerships for development and manufacturing [5].

Core Insights - Hypercharge Networks Corp. has appointed Kyle Moncrief as Vice President of Corporate Development and Financial Planning & Analysis to enhance corporate strategy and revenue growth initiatives [1][2][3] - Moncrief brings 14 years of experience in capital markets and corporate development, having executed over 20 transactions worth more than $1 billion in enterprise value [3][4] - The company has also announced the resignation of co-founder Liam Firus from the Board of Directors, acknowledging his contributions to the company's growth [6][7] Leadership Appointment - Kyle Moncrief will focus on corporate strategy, long-term planning, and enterprise value creation, working closely with executive leadership to advance capital deployment and strategic partnerships [2][3] - Moncrief's previous roles include VP at Zones Technologies and senior positions at Finning and 4Refuel, where he contributed to significant growth through partnerships and acquisitions [4] Stock Options and Equity Grants - In connection with his appointment, Moncrief has been granted 1,333,333 stock options with an exercise price of $0.08, vesting over three years [5] - CEO David Bibby has been granted 3,041,609 stock options and 3,041,609 restricted share units, also exercisable at $0.08, to recognize his leadership and contributions [9] Company Overview - Hypercharge Networks Corp. is a leading provider of smart electric vehicle charging solutions, committed to accelerating EV adoption and supporting the transition to a carbon-neutral economy [10]